Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses promising clinical trials in cellular therapies for multiple myeloma. The Phase II trial KarMMa (NCT03361748) reproduced the results from the Phase I trial with a global cohort. The study investigated idecabtagene vicleucel (bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma. The idecabtagene vicleucel treatment showed a significant clinical response in previously treated multiple myeloma patients and also indicated 20 months of progression-free survival. Other promising trials are CARTITUDE-1 (NCT03548207) and EVOLVE (NCT03430011) which show similar efficacy for JNJ-68284528 and JCARH125 with low toxicity. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.